ReviewDigestive diseases and sciences2022
Nonalcoholic Fatty Pancreas Disease: Role in Metabolic Syndrome, "Prediabetes," Diabetes and Atherosclerosis.
Review in Digestive diseases and sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 75 citations in OpenAlex.
- Interrelationships Between Key Cardiovascular Risk Factors, Chronic Kidney Disease and Metabolic Dysfunction-Associated Steatotic Liver Disease.Current cardiology reports · 2026Review
- Development and validation of a clinical prediction model for fatty pancreas disease: from CT-based indicators to an easy-to-use prediction application.Nutrition journal · 2026Article
- Intra-pancreatic fat deposition links to widespread systemic health risks: UK Biobank prospective cohort study.Insights into imaging · 2026Article
- Obesity surgery improves metabolic dysfunction-associated steatotic liver disease and type 2 diabetes - MRI and biochemical analysis of liver and pancreas.Surgery open science · 2026Article
- Review
- Fatty Liver and Pancreatic Steatosis in Patients with Chronic Hepatitis B and C and Wilson's Disease.Sisli Etfal Hastanesi tip bulteni · 2026Article
- Pancreatic steatosis is not associated with advanced steatohepatitis or fibrosis in metabolic dysfunction-associated steatotic liver disease.World journal of gastroenterology · 2025Article
- High serum uric acid as a marker for fatty pancreas disease in Chinese women with overweight/obesity.BMC endocrine disorders · 2025Article
- From NAFPD to MAFPD: a literature review of implications of a nomenclature change.Hepatobiliary surgery and nutrition · 2025Review
- Dosimetric parameters and clinical outcomes of photobiomodulation in diabetic neuropathy: a concise review.Lasers in medical science · 2025Review
- Relationship Between Liver Steatosis, Pancreas Steatosis, Metabolic Comorbidities, and Subclinical Vascular Markers in Children with Obesity: An Imaging-Based Study.Journal of clinical medicine · 2025Article
- Significance of Pancreatic Steatosis as a Predictor of New-Onset Diabetes Mellitus Following Pancreatectomy.Pancreas · 2025Article
- Understanding the association of intrapancreatic fat deposition with adiposity and components of metabolic syndrome in children and adolescents: a systematic review and meta-analysis.EClinicalMedicine · 2025Article
- Pancreatic changes in patients with visceral fat obesity: an evaluation with contrast-enhanced dual-energy computed tomography with automated three-dimensional volumetry.La Radiologia medica · 2025Article
- Triglyceride-glucose index is independently associated with fatty pancreas disease in Chinese elderly.BMC endocrine disorders · 2025Article
- Terazosin, a repurposed GPR119 agonist, ameliorates mitophagy and β-cell function in NAFPD by inhibiting MST1-Foxo3a signalling pathway.Cell proliferation · 2025Article
- Metabolic Dysfunction Associated-Steatotic Liver Disease (MASLD) and Cardiovascular Risk: Embrace All Facets of the Disease.Current cardiology reports · 2025Review
- Effects of lifestyle intervention and supplementation with insoluble oat fiber on cognitive functions in patients with prediabetes: a secondary analysis of the Optimal Fiber Trial.Frontiers in nutrition · 2025Article
- Association between the aspartate aminotransferase-to-alanine aminotransferase ratio and the reversion to normoglycemia in people with impaired fasting glucose: a 5-year retrospective cohort study.Frontiers in endocrinology · 2025Article
- Huazhi Rougan Granule Alleviates Liver and Intestinal Damage in Non-Alcoholic Fatty Liver Disease by Regulating miR-122 Expression and TLR4/MyD88/NF-κB Pathway Activation.Combinatorial chemistry & high throughput screening · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fat accumulation in the pancreas associated with obesity and the metabolic syndrome (MetS) has been defined as "non-alcoholic fatty pancreas disease" (NAFPD). The aim of this review is to describe the association of NAFPD with obesity, MetS, type 2 diabetes mellitus (T2DM) and atherosclerosis and also increase awareness regarding NAFPD. Various methods are used for the detection and quantification of pancreatic fat accumulation that may play a significant role in the differences that have been observed in the prevalence of NAFPD. Endoscopic ultrasound provides detailed images of the pancreas and its use is expected to increase in the future. Obesity and MetS have been recognized as NAFPD risk factors. NAFPD is strongly associated with non-alcoholic fatty liver disease (NAFLD) and it seems that the presence of both may be related with aggravation of NAFLD. A role of NAFPD in the development of "prediabetes" and T2DM has also been suggested by most human studies. Accumulation of fat in pancreatic tissue possibly initiates a vicious cycle of beta-cell deterioration and further pancreatic fat accumulation. Additionally, some evidence indicates a correlation between NAFPD and atherosclerotic markers (e.g., carotid intima-media thickness). Weight loss and bariatric surgery decreases pancreatic triglyceride content but pharmacologic treatments for NAFPD have not been evaluated in specifically designed studies. Hence, NAFPD is a marker of local fat accumulation possibly associated with beta-cell function impairment, carbohydrate metabolism disorders and atherosclerosis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.